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Introduction
Extensive research over the past decade has led to major 
advances in our understanding of the importance of 
vitamin D in health and disease. A PubMed search, using 
the term “vitamin D”, limited to English articles that have 
been published in the past five years, revealed over 10 000 
results. This renewed interest may be attributed to large 
studies that confirm the high level of nutritional vitamin D 
deficiency worldwide, to observational studies and meta-
analyses that show a strong association between vitamin 
D deficiency and various chronic diseases, as well as to 
new insights that have emerged regarding the autocrine, 
paracrine and nonhormonal functions of activated vitamin 
D in humans.1 The above information explosion poses a 
challenge for clinicians. This article aims to provide a brief 
review of the issues that relate to vitamin D deficiency in the 
South African context.
Overview of vitamin D metabolism
Vitamin D exists in two forms: D2 (ergocalciferol) and 
D3 (cholecalciferol). There are also numerous circulating 
metabolites in humans. Vitamin D3 is produced in the skin 
under the influence of ultraviolet light (80%), or can be 
obtained from the diet (fatty fish and egg yolks). Vitamin 
D2 is found in some plant sources and manufactured 
commercially by the irradiation of ergosterol produced by 
yeast.2 Supplementation can either be with vitamin D2 or D3. 
Both forms can be stored in adipose tissue or can undergo 
hydroxylation in the liver, whereby 25-hydroxyvitamin D 25 
(OH) vitamin D (calcidiol) [25(OH)D] is produced. This form 
is converted in the kidney (via 1α hydroxylase) to 1,25(OH)2 
vitamin D (calcitriol), the  biologically active form of vitamin D.
The vitamin D receptor is a nuclear receptor of the thyroid 
hormone receptor superfamily. All tissues in the body 
express the vitamin D receptor and can respond to circulating 
calcitriol.3 Furthermore, it has been shown that many 
tissues, including the colon, pancreas, breast, prostate, 
immune system, macrophages, vascular endothelium, 
epidermis and placenta, possess the enzymes to produce 
1,25(OH)2 vitamin D locally.  This may explain why vitamin D 
appears to play an essential role in overall health.3,4
Measurement of vitamin D status
The 25(OH)D level best reflects the body’s overall vitamin 
D status, as it is more stable than 1,25(OH)2 vitamin D, 
with a much longer half-life.5 The level reflects both dietary 
intake and sunlight exposure, as well as converted vitamin 
D, previously stored in fat. However, 25(OH)D assays are 
not standardised at the present time. It is essential for the 
clinician to use method-specific reference ranges and carry 
out patient follow-up at the same laboratory.
Vitamin D deficiency
Currently, normal vitamin D status is defined as a 25(OH)D 
serum level of  > 30 ng/ml (> 75 nmol/l). The World Health 
Organization previously defined (true) deficiency as levels 
below 10 ng/ml (< 25 nmol/l).5 However, the lower limit of 
normal still remains a topic of much debate. More recently, 
the term “vitamin D insufficiency” has been introduced to 
describe suboptimal levels (typically between 10 and 30 
ng/ml (25-75 nmol/l) of 25(OH)D associated with adverse 
outcomes2,5 (Table I).
Various reviews have described functional measures that 
are used to evaluate the adequacy of vitamin D levels.1,2 
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These include the 25(OH)D level at which there is maximal 
intestinal calcium reabsorption and no further increase 
in 1,25(OH)2 vitamin D levels with replacement and the 
level which maximally suppresses parathyroid hormone 
(PTH) secretion. The measurement of 25(OH)D is the most 
suitable indicator of vitamin D status.2 In a South African 
study, it was found that PTH levels rose significantly once 
the 25(OH)D level dropped below 10 mg/ml (25 nmol/l), but 
that more than half these patients still had calcium levels in 
the normal range.6
There has been a substantial increase in the prevalence of 
vitamin D deficiency in the past few years, as demonstrated 
by population-based studies like the National Health and 
Nutrition Examination Survey (NHANES) in the USA, where 
25-30% of the population had frank vitamin D deficiency.1 
This was noted across all age groups. Males and females 
were equally affected and non-Caucasoid populations were 
at the highest risk. Associated factors with this decline in 
vitamin D levels include a decrease in the intake of milk 
products, more liberal sunscreen use and sun avoidance, 
race, season, as well as the global increase in the prevalence 
of obesity.1
Diseases and outcomes associated with 
vitamin D deficiency
The classic outcomes of vitamin D deficiency are nutritional 
rickets (affecting growing bone) and osteomalacia (in adults). 
However, recently, it has become apparent that there are 
numerous other skeletal, as well as interesting nonskeletal 
benefits in having adequate vitamin D levels.2 
These will be discussed here.
Skeletal health
Vitamin D is critical for bone health. Vitamin D levels are 
often lower in those who fracture. However, trials that 
assess the effectiveness of supplementation mostly include 
the addition of calcium as well. A Cochrane meta-analysis 
found no significant effect of vitamin D supplementation 
alone on the risk of fractures, but supplementation with both 
calcium and Vitamin D had a positive effect on the reduction 
of hip fractures in frail and institutionalised people.7
Observational studies indicate that there is an increased 
risk of falls in institutionalised persons that is associated 
with low vitamin D levels.8 This risk is also associated with 
poorer physical performance in community-dwelling older 
individuals and is a predictor of adverse events.9 Vitamin 
D supplementation reduces the risk of falls in older adults 
through effects on muscle and the nervous system (both 
central and peripheral), whereby it improves gait and 
balance.8,10
Vitamin D supplementation of > 800 IU per day, aiming to 
achieve 25(OH)D levels of at least 30 ng/ml, was somewhat 
favourable in preventing hip fractures and nonvertebral 
fractures in persons who were 65 years and older.11
Cardiovascular health
Observational data have linked vitamin D deficiency with 
a range of cardiovascular diseases, which include strokes, 
myocardial infarction and hypertension.12-14 Recently, a 
large study found reduced cardiovascular survival in vitamin 
D-deficient patients. Supplementing these patients was 
significantly associated with better survival.15 Interventional 
studies like these are encouraging, but many questions 
remain regarding dosing and optimal levels, as well as the 
issue of concomitant calcium supplementation (which is 
somewhat contentious at present).15
Diabetes mellitus
Low vitamin D is a risk factor for the development of 
type 1 diabetes mellitus, based on animal and human 
observational studies. Increased vitamin D intake is a 
possible preventative strategy for the disease.16 This may 
relate to the immunomodulatory actions of vitamin D, which 
influences lymphocytes and interleukins.17
Observational data suggest that altered vitamin D and 
calcium metabolism may also play a role in the development 
of type 2 diabetes mellitus.18,19 Our understanding of the 
exact mechanisms for this association remains incomplete 
and is an area of active research. Vitamin D receptors and 
binding proteins are present in pancreatic islet tissue. The 
role of vitamin D in the pathogenesis of diabetes seems 
relate to its role in the regulation of plasma calcium, which 
in turn regulates insulin secretion. In addition, it also has 
a direct effect on pancreatic B cells, as well as effects on 
inflammatory mediators.17,20 It has been demonstrated that 
obesity (a known risk factor for type 2 diabetes mellitus) is 
associated with low vitamin D levels. However, interventional 
studies showing benefit are still lacking at this stage.21
Skin diseases
In a country renowned for its sunshine, the beneficial 
as well as harmful effects of ultraviolet (UV) radiation are 
apparent. Protection against UV radiation is advocated in 
order to reduce the risk of cancer, although this can lead 
to a marked reduction in vitamin D levels.22 Further work is 
necessary to define the adequate amount of sun exposure 
to obtain optimal vitamin D levels, especially in the South 
African climate. However, it is imperative that a balanced 
view is maintained of the positive (vitamin D) and negative 
(skin cancer risk) effects of UV radiation. Monitoring and 
supplementation with vitamin D is essential in patients at 
risk of developing vitamin D deficiency (the elderly and 
Table I: Interpretation of 25-hydroxyvitamin D 25 (OH) vitamin D level
Normal status > 30 ng/ml (75 nmol/l)
Vitamin D insufficiency 10-30 ng/ml
25-75 nmol/l
Vitamin D deficiency < 10 ng/ml
< 25 nmol/l
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people who cover up for religious reasons).23 Interestingly, 
topical vitamin D derivatives are also used in the treatment 
of psoriasis.24
Infectious diseases and immunity
The relationship between vitamin D and the immune 
system was recognised a number of years ago with the 
demonstration of increased circulating levels of 1,25(OH)2D 
and hypercalcuria and hypercalcaemia in sarcoidosis. This 
is because of the increased local activity of 1-α-hydroxylase 
which is found in activated macrophages.25 It is now 
clear that dysregulation of vitamin D homeostasis is not 
only present in sarcoidosis, but also in other forms of 
granulomatous disease and cancer.
Today, it is recognised that vitamin D plays a more active role 
in the immune system.26 It is involved in the differentiation of 
monocytes to mature phagocytic macrophages, and more 
recently, has been demonstrated to affect the phagocytic 
process by stimulating the expression of the antibacterial 
protein, cathelicidin.27 Regulation of this protein has also 
been described in other cell types, notably keratinocytes, 
lung epithelial cells, myeloid cells and placental 
trophoblasts.26
Low-serum vitamin D levels are associated with a higher 
risk of active tuberculosis.28 Considerable work has been 
carried out into the role of vitamin D supplementation in the 
management of tuberculosis, but to date the results have 
been conflicting. It has not been demonstrated to have a 
convincing effect on sputum conversion or mortality.29,30
Vitamin D deficiency is also very prevalent in human 
immunodeficiency virus (HIV)-infected individuals.31 It has 
been shown that there is inadequate 1-α-hydroxylation 
and decreased levels of 1,25(OH)2, possibly because 
of increased levels of TNF-α. This may contribute to the 
impaired immune response and the pathogenesis of HIV-
related immunodeficiency.32 Moreover, non-nucleoside 
reverse transcriptase inhibitors, notably efavirenz, have 
been implicated in lowering vitamin D levels.33
Observational epidemiological studies have shown an 
increased risk of other viral infections (influenza and 
respiratory tract infections) associated with vitamin D 
deficiency.34
Cancer risk
The active form of vitamin D, calcitriol, has been shown to 
slow tumour growth in animal models.35 Various mechanisms 
are postulated, including inhibition of cell proliferation 
and enhanced apoptosis, inhibiting angiogenesis and 
suppressing inflammation and metastases. Observational 
studies also show vitamin D deficiency to be associated 
with an increased risk of developing cancer, notably breast, 
colon and prostate cancer.36 As a result of encouraging 
preclinical data, vitamin D has been studied extensively as 
an anti-cancer drug, but the results have been disappointing 
to date.37
Rheumatologic diseases
Vitamin D is thought to protect against rheumatic diseases 
[rheumatoid arthritis (RA) and systemic lupus erythematosus 
(SLE)] through its effects on immune tolerance.27 A lower 
vitamin D level is associated with more severe and active 
disease in RA.38 The seasonal variation in vitamin D levels 
(lower in winter and higher in summer) negatively correlates 
with disease activity both in RA and SLE.22,24,39
Other diseases
Vitamin D deficiency has also been associated with various 
other diseases, including multiple sclerosis,40 asthma,41 
schizophrenia,42 gastrointestinal and liver disease43 and 
dementia.44
So how much is enough?
There is little consensus in the literature regarding the 
exact dosing, as well as optimal route of administration 
that is most beneficial. It is recommended that vitamin 
D supplementation should not be offered routinely, but 
that individuals at risk of deficiency (Table II) should be 
screened. In cases of severe deficiency, large doses (e.g. a 
once-weekly dose of 50 000 IU of D2 or D3 for six weeks, 
followed by a maintenance dose of 400-1000 IU per day) 
may be required, and this may even increase in obese 
patients, patients with malabsorption syndromes and 
patients on medication that affects vitamin D metabolism.45
Table II: Individuals at risk of vitamin D deficiency45
Rickets, osteomalacia
Osteopororsis
Chronic kidney disease
Liver disease
Malabsorption syndromes
  Cystic fibrosis
  Inflammatory bowel disease
  Baratric surgery
  Radiation enteritis
  Coeliac disease
  Chronic pancreatitis
Hyperparathyroidism
Medications
  Anti-seizure
  Glucocorticoids
  Acquired immune deficiency syndrome 
  Antifungals, e.g. ketoconazole
  Cholestyramine
Pregnant and lactating women
Older adults with a history of falls and nontraumatic fracture
Obese adults and children (body mass index > 30 kg/m2)
Conclusion
Vitamin D deficiency has been linked to a number of 
diseases. However, until now, interventional studies have 
been fairly disappointing, other than proving that vitamin D 
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is beneficial in skeletal disease. There is still some debate 
regarding the recommended daily allowance and the 
required optimal dose for standard supplementation, but 
meeting daily requirements in adults of 800-1000 IU should 
be adequate in most people who are at risk of vitamin D 
deficiency.
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